Myeloproliferative Neoplasms (MPN)
A group of chronic blood disorders in which the bone marrow overproduces red cells, white cells, or platelets, including polycythemia vera, essential thrombocythemia, myelofibrosis, and chronic myeloid leukemia.
- Subtype-specific molecular testing
- Thrombosis risk-guided management
- Access to targeted and novel therapies
- Most Common In
- Adults over 50
- Key Mutations Tested
- JAK2, CALR, MPL, BCR-ABL1
- Main Risk
- Thrombosis / Marrow Fibrosis
- Curative Option (select cases)
- Allogeneic Transplant
- Advanced Therapies
- TKIs, JAK Inhibitors, Trials
Condition Overview
Myeloproliferative neoplasms (MPNs) are a group of chronic disorders in which the bone marrow produces too many red blood cells, white blood cells, or platelets due to an acquired mutation in blood-forming stem cells. The classic MPNs include chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (MF), along with rarer subtypes such as chronic neutrophilic leukemia and chronic eosinophilic leukemia.
Types and Subtypes
MPNs are classified based on which blood cell lines are overproduced and the underlying driver mutation.
Symptoms and Signs
Symptoms vary by subtype but commonly relate to abnormal blood cell counts and an enlarged spleen.
Causes and Risk Factors
MPNs arise from acquired driver mutations in blood-forming stem cells; they are not typically inherited.
Diagnosis and Investigations
Diagnosis combines blood counts, bone marrow examination, and molecular testing to confirm the specific MPN subtype.
Staging and Risk Groups
Each MPN subtype uses its own risk model; broadly, risk is grouped by thrombosis risk (PV/ET) or prognostic scoring systems such as DIPSS for myelofibrosis.
Standard Treatment
Treatment is highly subtype-specific, ranging from targeted oral therapy in CML to risk-adapted management in PV, ET, and MF.
Advanced & Emerging Therapies
Targeted therapies have transformed MPN management, particularly in CML and myelofibrosis.
Targeted Therapy
Tyrosine kinase inhibitors (TKIs)
Cornerstone of CML treatment, achieving deep and durable molecular responses in most patients.
Targeted Therapy
JAK inhibitors
Used for symptomatic myelofibrosis and select polycythemia vera cases to reduce spleen size and symptoms.
Immunomodulatory Therapy
Interferon-based therapy
Considered for PV and ET, particularly in younger patients seeking to avoid cytotoxic agents.
Cellular Therapy
Allogeneic stem cell transplant
Offers curative potential for eligible higher-risk myelofibrosis or advanced-phase CML.
Investigational Agent
Novel JAK and combination inhibitors
Being studied in clinical trials to improve responses in myelofibrosis and treatment-resistant MPNs.
Biomarkers & Precision Medicine
Molecular testing is central to both diagnosis and ongoing management across MPN subtypes.
When to Seek 2nd Opinion
Given the range of MPN subtypes and treatment options, a second opinion can help confirm diagnosis and optimize therapy.
Clinical Trials & Research
Prognosis & Outcomes
Prognosis varies substantially by MPN subtype; CML treated with modern TKIs generally has an excellent long-term outlook, while myelofibrosis and advanced-phase disease carry more variable prognosis.
Supportive Care
Supportive care addresses symptom burden and reduces complications across MPN subtypes.
How CancerFax Helps You Explore Treatment Options
CancerFax helps you organize your blood counts, bone marrow, and molecular test results to clarify your specific MPN subtype and explore targeted therapy or transplant options.
Get a free case reviewFrequently Asked Questions
MPNs are a group of chronic blood disorders in which the bone marrow overproduces red cells, white cells, or platelets, including chronic myeloid leukemia, polycythemia vera, essential thrombocythemia, and myelofibrosis.
The classic types are chronic myeloid leukemia, polycythemia vera, essential thrombocythemia, and primary myelofibrosis, along with rarer forms such as chronic neutrophilic and chronic eosinophilic leukemia.
Fatigue, itching, an enlarged spleen, or abnormal blood counts on routine testing are common early indications.
Diagnosis involves blood counts, bone marrow biopsy, and molecular testing for mutations such as BCR-ABL1, JAK2, CALR, or MPL to confirm the specific subtype.
Most patients with CML achieve excellent long-term disease control with tyrosine kinase inhibitors, and some eventually qualify for treatment-free remission, though this is individualized.
The main risk is thrombosis, or blood clot formation, which is managed with aspirin, cytoreductive therapy, and risk factor control.
Treatment may include JAK inhibitors to reduce spleen size and symptoms, supportive care for anemia, and allogeneic stem cell transplant for eligible higher-risk patients.
Some MPNs, particularly myelofibrosis, can progress to acute myeloid leukemia over time, which is why ongoing monitoring is important.
Yes, mutations such as BCR-ABL1, JAK2, CALR, and MPL are central to confirming diagnosis, subtype, and treatment selection.
Yes. CancerFax can help you organize your blood count, bone marrow, and molecular test reports for expert review, support a second opinion request, and help identify targeted therapy, transplant, or clinical trial options, including coordination with specialists internationally.
Take the Next Step in Your MPN Care
Send your blood count, bone marrow, and molecular test reports to CancerFax for a structured review of your MPN subtype and treatment options.